Goldman Sachs’s ImmunityBio IBRX Stock Holding History

Goldman Sachs’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-50,000	Closed	-$411K	–	7118
2016 Q1	$411K	Hold	50,000	–	–	﹤0.01%	4950
2015 Q4	$866K	Buy	+50,000	New	+$742K	﹤0.01%	4441

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs's IBRX Position: Q2 2026 in Review

Goldman Sachs reduced its ImmunityBio (IBRX) stake by 0.09% in Q2 2026, selling an estimated $21.2K and leaving 3,234,277 shares worth $28.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2324.

Goldman Sachs first reported a position in IBRX in Q4 2015 and has held it in 39 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

Goldman Sachs held 3,234,277 shares of ImmunityBio worth $28.3M as of Q2 2026.
Goldman Sachs sold 2,801 ImmunityBio shares in Q2 2026, an estimated $21.2K.
ImmunityBio made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #2324 holding.
Goldman Sachs first reported a position in ImmunityBio in Q4 2015 and has held it in 39 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.